Research indicates that HCV core protein also downregulates p16 levels via ubiquitin-proteasome pathway degradation, releasing its inhibition on CDK4/6 and stimulating human hepatocellular carcinoma cell growth (Figure 2) (Cha et al., 2021). Here, CDK4 is linked to hepatocellular carcinoma.